Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors

SIMPLE SUMMARY: The capecitabine/temozolomide (CAPTEM) regimen has proven activity in pancreatic neuroendocrine tumors (NETs); however, data are limited in NETs of the small bowel. To observe whether this regimen has activity in this patient population, we conducted a retrospective study of all pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Toubah, Taymeyah, Morse, Brian, Strosberg, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870244/
https://www.ncbi.nlm.nih.gov/pubmed/35200546
http://dx.doi.org/10.3390/curroncol29020046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870244/
https://www.ncbi.nlm.nih.gov/pubmed/35200546
http://dx.doi.org/10.3390/curroncol29020046

Ejemplares similares